Literature DB >> 24713000

Tau phosphorylation and tau mislocalization mediate soluble Aβ oligomer-induced AMPA glutamate receptor signaling deficits.

Eric C Miller1, Peter J Teravskis, Benjamin W Dummer, Xiaohui Zhao, Richard L Huganir, Dezhi Liao.   

Abstract

In our previous studies, phosphorylation-dependent tau mislocalization to dendritic spines resulted in early cognitive and synaptic deficits. It is well known that amyloid beta (Aβ) oligomers cause synaptic dysfunction by inducing calcineurin-dependent AMPA receptor (AMPAR) internalization. However, it is unknown whether Aβ-induced synaptic deficits depend upon tau phosphorylation. It is also unknown whether changes in tau can cause calcineurin-dependent loss of AMPARs in synapses. Here, we show that tau mislocalizes to dendritic spines in cultured hippocampal neurons from APPSwe Alzheimer's disease (AD)-transgenic mice and in cultured rat hippocampal neurons treated with soluble Aβ oligomers. Interestingly, Aβ treatment also impairs synaptic function by decreasing the amplitude of miniature excitatory postsynaptic currents (mEPSCs). The above tau mislocalization and Aβ-induced synaptic impairment are both diminished by the expression of AP tau, indicating that these events require tau phosphorylation. The phosphatase activity of calcineurin is important for AMPAR internalization via dephosphorylation of GluA1 residue S845. The effects of Aβ oligomers on mEPSCs are blocked by the calcineurin inhibitor FK506. Aβ-induced loss of AMPARs is diminished in neurons from knock-in mice expressing S845A mutant GluA1 AMPA glutamate receptor subunits. This finding suggests that changes in phosphorylation state at S845 are involved in this pathogenic cascade. Furthermore, FK506 rescues deficits in surface AMPAR clustering on dendritic spines in neurons cultured from transgenic mice expressing P301L tau proteins. Together, our results support the role of tau and calcineurin as two intermediate signaling molecules between Aβ initiation and eventual synaptic dysfunction early in AD pathogenesis.
© 2014 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  Abeta oligomers; Alzheimer's disease; dendritic spines; mEPSC; synaptic deficits; tau phosphorylation

Mesh:

Substances:

Year:  2014        PMID: 24713000      PMCID: PMC4123852          DOI: 10.1111/ejn.12507

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  82 in total

Review 1.  LTP and LTD: an embarrassment of riches.

Authors:  Robert C Malenka; Mark F Bear
Journal:  Neuron       Date:  2004-09-30       Impact factor: 17.173

2.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

3.  Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord.

Authors:  U Arvidsson; M Riedl; S Chakrabarti; J H Lee; A H Nakano; R J Dado; H H Loh; P Y Law; M W Wessendorf; R Elde
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

4.  Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus.

Authors:  Qi-Sheng Chen; Wei-Zheng Wei; Takeshi Shimahara; Cui-Wei Xie
Journal:  Neurobiol Learn Mem       Date:  2002-05       Impact factor: 2.877

Review 5.  Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.

Authors:  Jian-Zhi Wang; Yi-Yuan Xia; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

6.  Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling.

Authors:  Hafiz Mohmmad Abdul; Michelle A Sama; Jennifer L Furman; Diana M Mathis; Tina L Beckett; Adam M Weidner; Ela S Patel; Irfan Baig; M Paul Murphy; Harry LeVine; Susan D Kraner; Christopher M Norris
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

7.  Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin.

Authors:  Hans Zempel; Julia Luedtke; Yatender Kumar; Jacek Biernat; Hana Dawson; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  EMBO J       Date:  2013-09-24       Impact factor: 11.598

Review 8.  Role of tau protein in both physiological and pathological conditions.

Authors:  Jesus Avila; Jose J Lucas; Mar Perez; Felix Hernandez
Journal:  Physiol Rev       Date:  2004-04       Impact factor: 37.312

9.  Activation of CaMKII in single dendritic spines during long-term potentiation.

Authors:  Seok-Jin R Lee; Yasmin Escobedo-Lozoya; Erzsebet M Szatmari; Ryohei Yasuda
Journal:  Nature       Date:  2009-03-19       Impact factor: 49.962

Review 10.  The GSK3 hypothesis of Alzheimer's disease.

Authors:  Claudie Hooper; Richard Killick; Simon Lovestone
Journal:  J Neurochem       Date:  2007-12-18       Impact factor: 5.372

View more
  50 in total

Review 1.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

2.  Local and Use-Dependent Effects of β-Amyloid Oligomers on NMDA Receptor Function Revealed by Optical Quantal Analysis.

Authors:  Brooke L Sinnen; Aaron B Bowen; Emily S Gibson; Matthew J Kennedy
Journal:  J Neurosci       Date:  2016-11-09       Impact factor: 6.167

3.  Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.

Authors:  Yongli Xie; Yibin Tan; Youbiao Zheng; Xiubo Du; Qiong Liu
Journal:  J Biol Inorg Chem       Date:  2017-05-13       Impact factor: 3.358

4.  Neurophysiological signatures in Alzheimer's disease are distinctly associated with TAU, amyloid-β accumulation, and cognitive decline.

Authors:  Kamalini G Ranasinghe; Jungho Cha; Leonardo Iaccarino; Leighton B Hinkley; Alexander J Beagle; Julie Pham; William J Jagust; Bruce L Miller; Katherine P Rankin; Gil D Rabinovici; Keith A Vossel; Srikantan S Nagarajan
Journal:  Sci Transl Med       Date:  2020-03-11       Impact factor: 17.956

5.  Mechanical injuries of neurons induce tau mislocalization to dendritic spines and tau-dependent synaptic dysfunction.

Authors:  Nicholas J Braun; Katherine R Yao; Patrick W Alford; Dezhi Liao
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-02       Impact factor: 11.205

6.  Phosphorylation in two discrete tau domains regulates a stepwise process leading to postsynaptic dysfunction.

Authors:  Peter J Teravskis; Breeta R Oxnard; Eric C Miller; Lisa Kemper; Karen H Ashe; Dezhi Liao
Journal:  J Physiol       Date:  2019-07-07       Impact factor: 5.182

Review 7.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

8.  Intrahippocampal administration of a domain antibody that binds aggregated amyloid-β reverses cognitive deficits produced by diet-induced obesity.

Authors:  Danielle M Osborne; Dennis P Fitzgerald; Kelsey E O'Leary; Brian M Anderson; Christine C Lee; Peter M Tessier; Ewan C McNay
Journal:  Biochim Biophys Acta       Date:  2016-03-10

9.  Tau Mislocation in Glucocorticoid-Triggered Hippocampal Pathology.

Authors:  Sara Pinheiro; Joana Silva; Cristina Mota; João Vaz-Silva; Ana Veloso; Vítor Pinto; Nuno Sousa; João Cerqueira; Ioannis Sotiropoulos
Journal:  Mol Neurobiol       Date:  2015-09-02       Impact factor: 5.590

10.  Tau accumulation induces synaptic impairment and memory deficit by calcineurin-mediated inactivation of nuclear CaMKIV/CREB signaling.

Authors:  Yaling Yin; Di Gao; Yali Wang; Zhi-Hao Wang; Xin Wang; Jinwang Ye; Dongqin Wu; Lin Fang; Guilin Pi; Ying Yang; Xiao-Chuan Wang; Chengbiao Lu; Keqiang Ye; Jian-Zhi Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.